Health technology assessment (HTA) has been used to support healthcare decision making for high technology medicines in China. This article provides China’s experience in using HTA to support healthcare decision making on health insurance reimbursement for cancer immunotherapies. It explains assessment methods for decision making based on HTA methods and evidence. Main challenges on HTA application are identified. It also provides lesson learn China on HTA which can be useful for other countries dealing with challenges on financing of high technology medicines.